Physician profile
John B Flaks
NPI 1366424939
$390.53
in general payments reported to CMS, 2019-2025
11 companies · $313 in 2025
The $313 reported for 2025 was more than what 87% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.43 · 2021: $18.20 · 2022: $33.15 · 2024: $13.25 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $146.01 | 2025 | On-Q Pump and Accessories |
| Ardelyx, INC. | $37.48 | 2025 | Ibsrela |
| Madrigal Pharmaceuticals | $36.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Pacira Pharmaceuticals Incorporated | $32.30 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.42 | 2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.27 | 2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $19.19 | 2025 | Dupixent |
| Mylan Pharmaceuticals INC. | $19.05 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.33 | 2025 | Iqirvo |
| Genzyme Corporation | $18.33 | 2025 | |
| Ethicon US, LLC | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Flaks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.